Nektar Therapeutics

@NektarNews

Official Twitter feed for Nektar’s Media Team, we’re tweeting on what we find engaging. Nektar’s Twitter guidelines can be found here:

San Francisco, CA
Vrijeme pridruživanja: listopad 2011.

Tweetovi

Blokirali ste korisnika/cu @NektarNews

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @NektarNews

  1. 4. velj

    Our collaboration with leading research institutions like provide valuable insight as we work toward developing novel therapies to fight .

    Poništi
  2. 4. velj

    On we thank the patients and physicians for their collaboration and participation in clinical trials, moving us closer to our common goal: curing . Nektar is committed to bringing hope to people with cancer by creating new medicines to treat this disease.

    Poništi
  3. 3. velj

    New research published with in from researchers : Results show how bempeg works synergistically with multiple immune-based therapies to enhance T-cell-mediated tumor control. Click here to read:

    Poništi
  4. 3. velj

    New research published with in from the team at Antoni Ribas’ Lab : ACT therapy supported by bempeg increases the proliferation, homing and persistence of anti-tumor T cells in melanoma models. Click here to read:

    Poništi
  5. 24. sij

    Dr. Nikhil Munshi discusses his research on NKTR-255 in multiple myeloma. via

    Poništi
  6. proslijedio/la je Tweet
    13. sij

    New sponsors of trek, Climb to Fight Cancer, Mar. 19-Apr. 4, 2020. Thanks to and ! Team now stands at 14 members. Room for 2 more people. Curious? Learn more about at 4:15pm Tues at Parc 55, Level 4, Davidson.

    Poništi
  7. 17. pro 2019.

    Nektar is proud to welcome Dr. Myriam Curet to our Board of Directors.

    Poništi
  8. 12. pro 2019.

    Dr. Rodríguez-Abreu presents the Phase 1/2 PROPEL study design at . View the poster:

    Poništi
  9. 10. pro 2019.

    Yesterday, at , Dr. Nina Shah presented a first-look at the trial design for our Phase 1 dose-escalation study of our IL-15 receptor agonist in relapsed/refractory non-Hodgkin and multiple . Learn more here:

    Poništi
  10. 9. pro 2019.

    Nektar’s Head of Research, Dr. Loui Madakamutil, with Dr. Rafael Fernandez from Dr. Nikhil Munshi’s lab presenting new preclinical data at . View the poster:

    Poništi
  11. 9. pro 2019.

    Clinical investigators, Dr. Nina Shah and Dr. Alan Tan , present the Phase 1 study design for NKTR-255 at View the poster:

    Poništi
  12. 9. pro 2019.

    Join us today for a presentation of our investigational therapy in collaboration with Nikhil Munshi’s lab at for multiple at in Hall B, Level 2 at 6:00 pm ET. Learn more:

    Poništi
  13. 9. pro 2019.

    Nektar's Takahiro Miyazaki and Dr. Mario Marcondes with Dr. Cassie Chou of as she presents new preclinical data at on combining NKTR-255 with CD19 CAR T immunotherapy. View the poster:

    Poništi
  14. 8. pro 2019.

    At ? Join us at 6 p.m. ET in Hall B to see our latest preclinical data, in collaboration with Cameron Turtle’s lab at , on our investigational IL-15 receptor agonist in combination with a CD19 immunotherapy. Learn more here:

    Poništi
  15. 6. pro 2019.

    Nektar is proud to partner with on our Phase 1 Study of NKTR-255: Cancer Treatment Centers of America Continues Pioneering Efforts in Immuno-Oncology; Doses First Patient in Novel Immunotherapy Clinical Trial Learn more:

    Poništi
  16. 21. stu 2019.

    Yesterday our Chief R&D Officer, Jonathan Zalevsky, PhD, presented at the conference. Click here to view the presentation:

    Poništi
  17. 21. stu 2019.

    Today at , our Head of Research, Loui Madakamutil, PhD, presented preclinical data for our investigational IL-15 receptor agonist and its potential benefits for therapies. Read more here:

    Poništi
  18. 21. stu 2019.

    Our head of in vivo pharmacology, Dr. Saul Kivimäe, presented on our investigational TLR agonist, NKTR-262, in combination with our investigational bempegaldesleukin in solid tumors at the 11th Annual . Learn more here:

    Poništi
  19. 10. stu 2019.

    Today at , we shared data on our investigational regulatory T cell stimulator in development with for the treatment of & other chronic conditions. Learn more:

    Poništi
  20. 10. stu 2019.

    This weekend at , Dr. Leo Nissola presented PORTER, a study evaluating the potential of biomarkers and immunotherapy combinations, including our I-O candidate, for the treatment of metastatic castration-resistant . Read more here:

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·